Evidence map›Paper›PMID 36177203›Full record

ArticleRoyal Society open science2022

Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents.

Carlos R Viera, Bradley T Stevens, Talysa Viera, Cameron Zielinski, Lee A Uranga, Snezna Rogelj, Praveen L Patidar, Rodolfo Tello-Aburto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Royal Society open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Carlos R VieraDepartment of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA.
Bradley T StevensDepartment of Biology, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA.
Talysa VieraDepartment of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA.
Cameron ZielinskiDepartment of Chemical Engineering, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA.
Lee A UrangaDepartment of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA.
Snezna RogeljDepartment of Biology, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA.
Praveen L PatidarDepartment of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA.
Rodolfo Tello-AburtoDepartment of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA.ORCID 0000-0001-8806-5762
New Mexico Institute of Mining and Technology · USNew Mexico State University · US

Funding

Structure-Activity Relationship Studies of Peptide Beta-Lactones as Proteasome Inhibitors and Anticancer AgentsR15GM124620 · NIGMS · NEW MEXICO INST OF MINING & TECHNOLOGY · PI TARTIS, MICHAELANN SHORTENCARIER · 2018 to 2018
$385k
NIGMS NIH HHS R15 GM124620
6 · The paper itself

Abstract

A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue

Indexed as

multiple myelomaproteasome inhibitorsβ-lactones

Identifiers

PMID36177203
PMCPMC9515629
OpenAlexW4297537444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.